Thomas Lodise, Pharm.D., Ph.D.
- Ph.D. in Epidemiology, University at Albany
- Pharm.D., Temple University School of Pharmacy
Courses Taught at ACPHS
- Drug Information (study design and statistics)
- Epidemiology I
- Epidemiology II
Integrating his dual interests in scholarship and patient care, Dr. Lodise’s overall research goal is to quantitatively enhance our current understanding of antimicrobial exposure-response relationships in patients with invasive bacterial infections. His research encompasses three interrelated domains: pharmacokinetics (PK)/pharmacodynamics (PD), epidemiology, and outcomes. His specific research objectives are 4-fold: develop “personalized” patient care strategies that improve outcomes; reduce the likelihood of drug-induced toxicities; minimize the emergence of antibiotic resistant infections; and reduce healthcare costs. In short, his research works to define the “right antibiotic at the right dose for the right patient.” Research cannot improve patient care unless the knowledge is transferable. To this end, he employs cutting-edge mathematical modeling techniques to identify patient- and treatment-related factors that promote optimal patient-centered outcomes. Advanced pharmacoepidemiologic and comparative effectiveness methodologies are also leveraged to determine optimal empiric and targeted treatment strategies for patients with antibiotic resistant infections. In addition, he uses state-of-the-art PK/PD methods to design antibiotic dosing schemes that optimize efficacy and minimize drug toxicity for implementation into clinical practice. He is particularly interested in identifying optimal dosing schemes for patient populations that are typically underrepresented in Phase III clinical. To date, he has published over 100 peer-reviewed articles in reputable scientific journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, Lancet Infectious Diseases, Chest, and Journal of Antimicrobial Chemotherapy. He has also secured over $1.5 million in grant funding from various sources.
2005 American College of Clinical Pharmacy (ACCP) Infectious Diseases PRN and the ACCP Research Institute
Infectious Diseases PRN Mini-sabbatical Mentor
2006 New York Chapter of American College of Clinical Pharmacy Researcher of the Year
2007 American College of Clinical Pharmacy (ACCP) Infectious Diseases PRN and the ACCP Research Institute
Infectious Diseases PRN Mini-sabbatical Mentor
2007 Clinical Infectious Diseases Award for Outstanding Journal Article Review
2008 Society of Infectious Diseases Pharmacists (SIDP) Young Investigator of the Year
2009 Clinical Infectious Diseases Award for Outstanding Journal Article Review
2010 Society of Infectious Pharmacists (SIDP) Impact Paper of the Year
2010 Clinical Infectious Diseases Award for Outstanding Journal Article Review
2013 Researcher of the Year (First Inaugural) Albany College of Pharmacy and Health Sciences
2015 Society of Infectious Pharmacists (SIDP) Impact Paper of the Year
2015 New York Chapter of American College of Clinical Pharmacy Researcher of the Year
- Dr. Lodise is a Clinical Pharmacist at the Stratton VA Medical Center in Albany, NY.
a. Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA. Vancomycin exposure in patients with MRSA bloodstream Infections: how much is enough? Clinical Infectious Diseases. 2014 Sep 1;59(5):666-75. PMID: 24867791
b. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano G. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clinical Infectious Diseases 2009 Aug 15;49(4):507-14. PMID: 19586413
c. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013 Feb;57(2):734-44. doi: 10.1128/AAC.01568-12. Epub 2012 Nov 19. Review. PubMed PMID: 23165462; PubMed Central PMCID: PMC3553731.
d. Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015 Jun;59(6):2978-85. doi: 10.1128/AAC.03970-14.Epub 2015 Mar 9. PubMed PMID: 25753631; PubMed Central PMCID: PMC4432113.
Dose optimization of antibiotics in critically ill patients with invasive infections. There have been tremendous strides in our understanding of antibiotic exposure-response relationships over the past 25 years. For many antibiotics, the “pharmacodynamic” or the exposure variable associated with outcomes has been identified. I have applied our understanding of antimicrobial pharmacodynamics (PD) into clinical practice by designing empirical antibiotics regimens across specialized patient populations that have a high probability of achieving the PD target linked to effect through the use of population pharmacokinetic modeling and Monte Carlo simulation.
a. Cardone KE, Chen WZ, Grabe DW, Batzold A, Manley HJ, Lodise TP. Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis. Journal Antimicrobial Chemotherapy. 2014 Jul;69(7):1873-6. PMID: 24722842
b. Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of Optimal Renal Dosage Adjustments for Traditional and Extended Infusion Piperacillin/Tazobactam Dosing Regimens in Hospitalized Patients. Antimicrobial Agents and Chemotherapy. 2010 Jan;54(1):460-5. Epub 2009 Oct 26. PMID: 19858253. PMCID: PMC2798531
c. Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrobial Agents and Chemotherapy. 2013 Feb;57(2):864-72. doi: 10.1128/AAC.02000-12. Epub 2012 Dec 3. PMID: 23208714. PMCID: PMC3553729.
d. Patel N, Pai MP, Rodvold KA, Lomaestro BM, Drusano GL, Lodise TP. Vancomycin: We Can’t Get There from Here. Clinical Infectious Diseases. 2011 Apr 15;52(8):969-74. PMID: 21460308.
Epidemiology and outcomes of hospitalized patients with infections due to antibiotic resistant bacteria. The prevalence of infections due to antibiotic resistant pathogens have increased dramatically over the last two decades and are a major public health threat among hospitalized patients throughout the world. Given the importance of early, appropriate therapy, my research focuses on the identification of patients at greatest risk for antibiotic infections. I also characterize the outcomes of patients with infections due to antibiotic resistant organisms.
a. Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin . J Antimicrob Chemother. 2014 Sep;69(9):2547-55. doi: 10.1093/jac/dku135. Epub 2014 May 19. PubMed PMID: 24840624.
b. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between Vancomycin MIC and Failure among Patients with MRSA Bacteremia Treated with Vancomycin. Antimicrobial Agents and Chemotherapy 2008 Sep;52(9):3315-20. Epub 2008 Jun 30. PMID: 18591266. PMCID: PMC2533486.
c. Patel N, McNutt LA, Lodise TP. Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008 Aug;52(8):2933-6. PubMed PMID: 18519718; PubMed Central PMCID: PMC2493121.
d. Lodise TP, Miller CD, Graves J, Furuno JP, McGregor JC, Lomaestro BM, Graffunder E, McNutt LA. Clinical Prediction Tool to Identify Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Multi-Drug Resistance. Antimicrobial Agents and Chemotherapy. 2007 Feb; 51(2):417-22. PMID: 17158943. PMCID: PMC1797724.
Pharmacoepidemiologic and comparative effectiveness studies to determine optimal treatment strategies for patients with antibiotic resistant infections. Currently, there are few completed clinical trials that define the optimal treatment strategies of patients with infections due to antibiotic resistant infections. There is high reliance on “real-world” pharmacoepidemiologic and comparative effectiveness studies to determine optimal management and treatment of infections due to antibiotic resistant pathogens. Through the use of state of art study design and statistical modeling techniques, my research uses real-world data to identify optimal treatment strategies that maximize the outcomes of patients with antibiotic resistant infections.
a. Lodise TP, Lomaestro BM, Graves J, Drusano GL. Larger Vancomycin Doses are Associated with an Increased Incidence of Nephrotoxicity. Antimicrobial Agents and Chemotherapy 2008 Apr;52(4); 1330-6. Epub 2008 Jan 28. PMID: 18227177. PMCID: PMC2292536
b. Lodise TP, Lomaestro BM, Drusano GL. Piperacillin/Tazobactam for Pseudomonas aeruginosa Infections: Clinical Implications of an Extended Infusion Dosing Strategy. Clinical Infectious Diseases. 2007 Feb 1; 44(3):357-63. PMID: 17205441.
c. Patel GW, Patel N, Lat A, Trombley K, Enbawe S, Manor K, Smith R, Lodise TP Jr. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis. 2009 Jun;64(2):236-40. doi: 10.1016/j.diagmicrobio.2009.03.002. PubMed PMID: 19500529.
d. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003 Jun 1;36(11):1418-23. Epub 2003 May 20. PubMed PMID: 12766837.